Skip to main content
Clinical Trials/NCT00120991
NCT00120991
Unknown
Phase 3

Off-Pump Coronary Artery Bypass Grafting Versus Conventional Coronary Artery Bypass Grafting on Postoperative Mortality and Morbidity, A Randomized Clinical Trial

Rigshospitalet, Denmark1 site in 1 country341 target enrollmentApril 2002

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Heart Disease
Sponsor
Rigshospitalet, Denmark
Enrollment
341
Locations
1
Primary Endpoint
All cause mortality
Last Updated
18 years ago

Overview

Brief Summary

There is evidence linking cardiopulmonary bypass to negative side effects when used for coronary artery bypass grafting. Coronary artery bypass grafting can be performed without the use of cardiopulmonary bypass. The purpose of this study is to determine the positive and negative effects of coronary artery bypass grafting with or without the use of cardiopulmonary bypass. The patients will be followed at least one year after surgery.

Detailed Description

Objectives: To evaluate the beneficial and harmful effects of off-pump coronary artery bypass grafting (OPCAB) versus conventional coronary artery bypass grafting (CCABG) using a heart- and lung machine in patients with three-vessel coronary artery disease. Trial population: Consecutive patients \> 54 years of age with three-vessel coronary artery disease with EuroSCORE of 5-16 undergoing elective or sub-acute coronary artery bypass grafting, giving written informed consent, and where randomisation can be accomplished preoperatively. The study will include 330 patients. Trial design: The Best Bypass Surgery Trial (BBS Trial) is a randomised trial. Patients will be randomised to one of two groups. The randomisation will be 1:1, in blocks, stratified by gender, age (55 to 65 years; \> 65 years), diabetes mellitus, and EuroSCORE (5-7; 8-10; 11-13; 14-16). The patients will be randomised to OPCAB surgery or CCABG surgery. The interventions: In the OPCAB group, the revascularization procedure will be performed on the beating heart with a stabilizer to demobilize the target coronary arteries. When access is needed for posterior coronary arteries a suction device will lift the heart. In the CCABG group, the revascularization procedure will be performed with the use of a heart- and lung machine in normothermia, aortic cross clamp, and with cold cardioplegic arrest. In both groups, the left internal mammary artery and saphenous vein grafts are standard graft material. Outcome measures: The aim of the study is to examine the value of OPCAB revascularization compared to CCABG revascularization on the following outcome measures: * Primary: The composite outcome measure of mortality (of all causes), acute myocardial infarction, cardiac arrest with successful resuscitation, low cardiac output syndrome, or major neurological deficit. * Secondary: Hyper dynamic shock; atrial fibrillation, respiratory insufficiency requiring intubation \>24 hours , need for pacing \> 1 day due to 2º AV-blockage or nodal rhythm; renal complications, i.e., serum creatinine \> 200 μmol/l, or need for acute dialysis; re-operation for bleeding, pneumonia; serious adverse events; duration of stay in intensive care unit; duration of stay in the hospital; quality of life after 3 and 12 month; graft patency at one year postoperatively defined by coronary angiography. In addition, cognitive function will be assessed after three and 12 months in the first 120 patients randomized.

Registry
clinicaltrials.gov
Start Date
April 2002
End Date
July 2008
Last Updated
18 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Known ischemic three vessel heart disease affecting one of the marginal coronary arteries
  • Age \> 54 years
  • Scheduled for elective or subacute CABG
  • EuroSCORE \> 4 and \< 17
  • The patient has signed written informed consent before randomization and surgery.

Exclusion Criteria

  • Previous heart surgery
  • Ejection fraction \< 30 %
  • Unstable preoperative condition, i.e., continuous infusion of inotropics on the day of the operation
  • Patient unable to give informed consent.

Outcomes

Primary Outcomes

All cause mortality

Time Frame: Short and long term

Acute myocardial infarction

Cardiac arrest with successful resuscitation

Low cardiac output syndrome/cardiogenic shock

Stroke

Need for renewed cardiac revascularization procedure

Secondary Outcomes

  • Duration of stay in the hospital
  • Quality of life after 3 and 12 month
  • Hyper dynamic shock
  • Atrial fibrillation during index admission
  • Need for pacing > 24 hours
  • Renal complications, i.e., increased serum creatinine
  • Reoperation for bleeding during index admission
  • Pneumonia
  • Respiratory insufficiency requiring intubation > 24 hours postoperatively
  • Serious adverse events
  • Duration of stay in intensive care unit
  • Graft patency at one year postoperatively defined by coronary angiography.

Study Sites (1)

Loading locations...

Similar Trials